The aim of the present study was to evaluate the relationship between the levels of neopterin among patients with benign and malignant breast disease and the relation with the stage of the malignant process. In this study, neopterin concentrations and enzyme activities of superoxide dismutase (SOD) and catalase (CAT) were determined in malign (n=30) and benign breast tumor patients (n=30) by high performance liquid chromatographic and spectrophotometric methods, respectively. Results were compared with a healthy control group (n=20). The correlations between neopterin, CAT and SOD were also evaluated in controls and patients. Urinary neopterin level of the control group was (mean value ± S.D.) 128.6 ± 64.6 µmol/mol creatinine. Neopterin concentrations in patients with breast malignancy were 153.6 ± 71.2 µmol/mol creatinine and 107.8 ± 32.1 µmol/mol creatinine in benign disorders patients. The mean neopterin level in the benign group was found to be statistically different from the malign tumor group (p = 0.039). SOD and CAT activities in controls were found as 3.57 ± 0.84 U/mg protein and 2.19 ± 0.20 U/mg protein, respectively. In patients with malignancy, the SOD activity was 3.84 ± 0.73 U/mg protein while CAT activity was 1.03 ± 0.13 U/mg protein. Patients with benign breast disorders, SOD activity was 4.09 ± 1.00 U/mg protein and CAT activity was 1.02 ± 0.18 U/mg protein. Whereas SOD activity did not differ between the groups of patients and controls, the mean catalase level in the control group was higher than in the benign and malign tumor groups (both p <0.001). Urinary neopterin concentration seems to be an important and useful biomarker in diagnosis of breast tumors in clinical practice.
Introduction
Breast carcinoma is one of the most common neoplasms in women and is a leading cause of cancer related deaths worldwide (1, 2) . There are many proposed mechanisms for the enhanced oxidative stress in breast cancer. One of the proposed pathways is the enhanced NADPH oxidase activity leading to over production of reactive oxygen species (ROS). Furthermore; neovascularization in the tumor tissue is unstable leading to frequent episodes of ischemia and reperfusion, thus enhancing the oxidative stress. This enhanced oxidative stress may be the underlying mechanism in the initiation and progression of the malignant process (3) . Oxidative damage results from the interaction of ROS with cellular macromolecules such as protein, lipid, DNA and leads to various pathological conditions including cardiovascular dysfunction, neurodegenerative disease and cancer (4, 5) . Breast cancer is now widely regarded as a genomic degenerative disease, the incidence of which grows exponentially as the population ages and as the genomic damage accumulates in the cell. In oxidative DNA damage, the formation of reactive oxygen and nitrogen species has been implicated as a linking factor in certain potential carcinogens (6) . As a result of this, ROS are being increasingly implicated in breast cancer development (7, 8) . On the other hand, the organism is equipped with counteracting antioxidant mechanisms classified in extracellular, membrane bound and cellu-lar mechanism. Glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT) are considered as cellular antioxidant defense mechanisms (9, 10) . They also act as anticarcinogens and inhibitors at initiation and promotion/transformation stage in carcinogenesis (11) . In previous studies, it has been shown that increased antioxidant enzyme activities have a great role in diminishing the growth of breast tumor, which was related to ROS (12, 13) .
Neopterin, D-erythro-trihydroxypropylpterin, is a stable, low-molecular-mass pteridine that is produced in humans and primates by monocytes and macrophages upon stimulation with interferon-γ (IFN-γ) (14) (15) (16) (17) . It is a representative of the cellular immune response and an indirect indicator of oxidative stress. Neopterin is also a useful biomarker to assess the intensity of the cell-mediated immunity and interactions with reactive oxygen intermediates and the promotion of oxidative stress in biological systems in response to various sources of injury. The term oxidative stress summarizes all events resulting in a distortion of the balance between the production of reactive oxygen or nitrogen species and the respective counterregulatory mechanisms towards a pro-oxidative state (15, 16, 18) . Although not being a tumor marker in the usual sense, a substantial number of studies have shown that measurement of neopterin is also of value in malignant disease. Generally, its concentrations in patients with malignant diseases depend strongly on tumor type, and among patients with a given tumor type, those with more advanced stage of the disease regularly show higher concentrations of neopterin than those with early stage tumors (17, 18) . Despite significant improvements in cancer diagnosis and treatment, approximately one quarter of breast cancer patients dies as a result of their disease. Therefore, the aim of the present study was to evaluate the relationship between the urine concentrations of neopterin among the patients with benign and malignant breast disease and the relation with the stage of the malignant process. In addition; the present study has been performed to investigate the antioxidant status of the patients and therefore SOD and CAT activities were measured for the groups as well.
Materials and Methods

Subjects
Sixty female patients operated between 2005 and 2006 were recruited for the study. Thirty of the patients had breast cancer (aged mean: 42.6 ± 10.2; range: 34 to 77) while the others had benign breast tumors (age: 38.0 ± 11.8; 17 to 60). The benign tumor group consisted of fibroadenoma (n = 23) and fibrocystic disease (n = 7) patients. The preoperative diagnosis of all breast cancer patients were confirmed by core biopsy. The exclusion criteria of the study were; obscure perioperative diagnosis, history of chemotherapy or radiotherapy, the patients with familial pattern of breast diseases, the patients who had a history of breast or other organ malignancies and presence of active infection at the time of sample collection. The 6th edition of the AJCC Cancer Staging system was used for staging (19) . The control group consisted of twenty healthy females (age 34.1 ± 6.57; 23 to 49) who worked as personnel in the same hospital. All controls were also questioned precisely to learn if they were systemically healthy, for the presence of active infection and whether they had received any medication during this period. The principles of the University Ethical Committee according to the Helsinki Declaration were followed during the whole study.
Samples
Blood samples were drawn into heparinized vaccutainer tubes and centrifuged for 15 min at 3,500 rpm. Erythrocytes were washed with phosphate buffered saline of pH 7.4. Hemolysates were prepared by addition of cold deionized water and centrifuged for the removal of cellular debris. The supernatants were used for the enzyme assays. At the same time, urine samples were collected early in the morning before the operation and kept from direct light. All samples were stored at -20°C until the assays.
Neopterin Measurement
Each urine sample was diluted with deionized water before determination of neopterin. Urinary neopterin levels were analyzed by high performance liquid chromatography (HPLC, HP Agilent1100). A column (25 cm X 4.6 mm) containing octadodecyl silica gel C18 (ODS, 5µm particle size, ACE5 C18), protected with a 4-cm guard column filled with the same material was used. Neopterin was isocratically eluted at a flow rate of 1 ml/min with 15 mM potassium dihydrogen phosphate buffer containing 2.5% methanol (v/v), pH 7.0 and quantified using a fluorescence detector (λex: 353 nm, λem: 438 nm). The neopterin levels were calculated as micromoles of neopterin per mole of creatinine. Creatinine concentrations were determined simultaneously by using an ultraviolet detector at the wavelength of 235 nm.
Enzyme Assays
Catalase activity was determined by the method of Aebi (20) . Superoxide dismutase activity was measured according to Marklund and Marklund (21) . The protein content of the samples was determined according to the modified Lowry method by Miller (22) .
Statistical analysis
All of the results were expressed as mean ± standard deviation (SD). Because some of the grouped data showed non-Gaussian distribution, the differences among the groups were evaluated with non-parametric Kruskal-Wallis analysis of variance, comparisons between two independent groups were made with the Mann-Whitney U-test and the correlations of the parameters were detected by Spearman non-parametric correlation test. Furthermore the results were confirmed with a multivariate regression model. p<0.05 was considered statistically significant.
Results
The mean urinary neopterin concentrations were 128.6 ± 64.6 and 132.4 ± 59.8 µmol/mol creatinine in controls and patients, respectively (Table 1 ). There was no significant difference between the controls and the patients in terms of neopterin levels. There was no significant difference between control group and the patients with benign disorders. Also, the average concentrations of urinary neopterin in control group and in patients with malignancy were not different. However, neopterin levels in the patients with breast cancer were significantly higher than the patients with benign disorders (p <0.05). In terms of neopterin levels; no significant difference was found between controls and the patients with fibroadenoma or fibrocystic disease. The results are shown in Table 1 and Figure 1 . In addition; there was no significant association between neopterin levels and the grade of the malignant disease (Table 1 and Figure 2) . A significant difference in specific CAT activities between controls and patients was found (p <0.001). The CAT activities between controls, patients with malignant and benign tumor were significantly different (both p <0.001). There were significant differences in CAT activities between control group and patients with fibroadenoma, fibrocystic disease (Table 1, Figure 1 ). On the other hand no significant association CAT activities and different stages of the malignant tumors (Table 1 and Figure 2 ).
There was no significant difference in terms of SOD activities of controls and patients. The SOD activities between among the controls and the patients with malignant and benign tumors were not statistically significant. The specific SOD activity did not differ between controls and the patients with fibroadenoma or fibrocystic disease (Table 1 and Figure 1 ). Furthermore; there was no significant correlation among the SOD activities and the tumor stages (Table  1 and Figure 2) .
According to the multivariate regression model (for considering how the three markers together relate to the tumor status), tumor status is a significant factor for the neopterin concentration (p = 0.039) and catalase activity (p <0.001), where the mean level of SOD does not differ statistically with the tumor status (p = Table 1 . Concentrations of neopterin in urine samples and enzyme activities in erythrocytes of the groups. Each result was expressed as mean ± SD. SOD = superoxide dismutase, CAT = catalase, * p = 0.039 (difference between groups with benign and malign tumor), # p <0.001 (different from controls) 0.177). According to the Post-Hoc analysis, the mean neopterin concentration in the benign group is statistically different from the malign tumor group (p = 0.031), and the mean catalase activity in the control group is statistically different from the benign and malign tumor groups (both p <0.001).
A positive correlation between CAT and SOD activity in both the whole patient group and patients with malignant tumors was found (Table 2 ). However, there was no correlation between SOD and CAT activities in controls or benign breast tumors. Furthermore, there were no significant associations between neopterin levels and SOD or CAT activities in patients with breast tumor (all p not significant; Table 2 ).
Discussion
It was shown that the presence of distant metastases, lymph node metastasis, tumor size, and urinary neopterin concentrations were the only variables that significantly predicted fatal outcome of women with breast cancer (23) . Previous studies suggest that clinical variables such as the presence of distant metastases, lymph node status, and tumor size had the greatest predictive power in determining a patient's outcome. It is important to stress that increased neopterin production, which is a sign of an activated cellular immune system, is not specific for a neoplastic disease. An im- provement of risk estimation might be achieved by combining the predictive immunological marker neopterin with a predictive tumor marker (15) . Observations have implied a more direct association between neopterin production and malignant growth because, in addition to the close relationship between the production of ROS and neopterin by the activated monocytederived macrophages, the effects of various reactive compounds are also modulated by neopterin derivatives. Thus, increased neopterin concentrations seem to be an indicator of increased oxidative stress in humans. ROS have been implicated in the initiation and promotion of carcinogenesis, and direct effects on growth factors and other signaling pathways of both antioxidants and oxidants have been demonstrated (15) .
Oxygen is utilized by various enzymes as electron acceptor leading to the formation of a series of ROS with unpaired electrons like superoxide anion or hydroxyl radical. These species are prone to react immediately with cellular macromolecules thereby causing cellular damage; namely the oxidative stress. Oxidative damage accumulates during the life cycle, and radical related damage to DNA, proteins and lipids have been proposed to play a key role in the development of age dependent diseases such as cancer (24, 25) . On the other hand, activation of the host immune system in patients with viral infections, autoimmune disorders and malignancies are also often accompanied by alterations in the production of pteridines. During cellular immune response, activated T-lymphocytes release IFN-γ, which stimulates human monocytes/macrophages for the production of neopterin (16, 26, 27) . It has been suggested that the relationship between oxidative stress and macrophage activation can be evaluated by measuring concentrations of neopterin, which has a potential role in processes mediated by free oxygen radicals (17, (28) (29) (30) (31) . Neopterin levels in body fluids can be regarded as an indirect estimate of the degree of oxidative stress during cellmediated immune response. The amounts of neopterin produced by activated monocytes/macrophages correlate with their capacity to release ROS. Neopterin concentrations reflect activation of cellular immunity and endogenous release of IFN-γ and reflect the level of the oxidative stress caused by activation of the immune system (16, 26) . Furthermore, it is demonstrated that neopterin levels are highly dependent on age in children but, on the other hand, they are strongly correlated to gender in adults, and for this reason the differences in the age of the patients and control groups in our study does not have any significant impact on the neopterin levels (32) . In several diseases, neopterin status correlates with the extent and activity of the disease. Significant associations between higher neopterin concentration and higher stage of disease were established in infectious syndromes, autoimmune disorders, and certain malignant neoplasia. Moreover, neopterin levels are of predictive value in patients with several types of cancer (16, 17, 28, 29) .
An increase in neopterin concentrations in patients with cancer has been well documented, but neopterin levels are elevated only in a minority of patients with breast carcinoma. In agreement with earlier reports (15, 25, 33) , we observed an increase in urinary neopterin in patients with breast cancer. Elevated neopterin levels have been associated with higher grade. Similarly, Melichar et al. have also found this correlation, and they have reported higher frequency of increased urinary neopterin in patients with advanced disease. Increased urinary neopterin concentration was a significant prognostic factor in both univariate and multivariate analysis. Slightly elevated serum neopterin concentrations have been observed in breast cancer survivors with chronic fatigue (24, 25, 33) .
Oxidative stress as a result of enhanced hydrogen peroxide production as well as other reactive oxygen species is accepted as one of the causative factors for breast carcinoma (3) . CAT enzyme is a defense mechanism against these oxidative assaults. It is a possibility that CAT is readily low in these patients and therefore tumor has actually developed. Another explanation may be that it can be low due to over consumption. Furthermore; SOD is responsible for hydrogen peroxide production from superoxide anion and therefore reduction in catalase activity may be the result of unchanged SOD activity in the SOD resulting in the reduced peroxide formation.
We observed a significant difference in neopterin levels between malignant and benign breast tumors. Briefly, our results point out that the urinary neopterin seems to be an important and useful biomarker in diagnosis of breast tumors in clinical practice. Especially, it may be of use in distinguishing tumor types. On the other hand, it is apparent that further observations and comprehensive studies, especially with larger number of cases are needed to confirm the validity of neopterin as a biomarker for breast tumors. We did not find any correlation between CAT or SOD activity and neopterin, as an indirect oxidative stress marker. However, there had been a positive correlation with antioxidant enzymes CAT and SOD in malignant tumor patients but not in benign tumors. It is known that there is a distinct correlation between malignancies and oxidative stress. In antioxidant enzymes it can be expected to observe a positive correlation to protect the body against the disease. We think that the present research has a crucial role for future studies on this matter as well as screening urinary neopterin profile may be beneficial in differential diagnosis of breast tumors.
